We are advancing a robust pipeline of innovative therapeutics aimed at transforming patient care in neurology, inflammatory skin diseases, and autoimmune conditions. Our portfolio includes five programs, each grounded in cutting-edge science and supported by a strong body of research.  

Our approach prioritizes therapies with the potential to be best-in-class, targeting significant unmet needs in major commercial markets. Program selection is driven by the strength of the scientific hypothesis and compelling supporting evidence, ensuring that each initiative has the potential to redefine standards of care and improve patient outcomes.